Lupin has acquired three key anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—from Boehringer Ingelheim. The move will enhance Lupin’s diabetes portfolio, offering treatment options for millions of patients in India.
Lupin Limited has announced the acquisition of three key trademarks from Boehringer Ingelheim to enhance its diabetes portfolio in India.
The trademarks include Gibtulio (empagliflozin), Gibtulio Met (empagliflozin + metformin), and Ajaduo (empagliflozin + linagliptin).
The transfer of rights is expected by March 2025. Lupin has been co-marketing these products since 2016 and the full transfer will solidify its position in the Indian diabetes market, the company said in a press release on the stock exchanges.
The acquired drugs, belonging to the SGLT-2 inhibitor class, help manage type 2 diabetes by improving glycemic control and reducing cardiovascular complications.
With diabetes affecting 80 million people in India, the acquisition strengthens Lupin’s commitment to providing effective and affordable treatments, addressing the growing need for diabetes care in the country.
On December 16, 2024, Lupin’s share price (NSE: LUPIN) traded 0.27% lower at ₹2,071.20 as of 10:15 AM on the NSE. The stock opened at ₹2,089.90, higher than the previous close of ₹2,076.75.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Dec 16, 2024, 10:26 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates